Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

ted in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, AMRIX(TM) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results including the FENTORA clinical trials discussed herein; prospects for regulatory approval, including approval of the FENTORA sNDA and the timing of the FDA's review period for this submission; manufacturing development and capabilities; market prospects for its products; sales and earnings guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at BioCentury,s NewsMakers in the Biotech ... a.m. Eastern time from the Millennium Broadway Hotel & Conference ... webcast of the presentation can be accessed at www.meipharma.com ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... SOMERSET, N.J., June 9 Alfacell Corporation,(Nasdaq: ACEL ... quarter,of fiscal 2008., The company recorded a net ... diluted common share, for the third fiscal quarter ended,April ... million, or $0.04,per basic and diluted common share, for ...
... Limited (LSE: SHP,Nasdaq: SHPGY), the global specialty biopharmaceutical ... lots of the ADHD patch DAYTRANA (lots,2750211 and ... DAYTRANA,patches do not meet their release liner removal ... have difficulties removing the,liners. This voluntary recall is ...
... 9 Amira Pharmaceuticals, a small,molecule pharmaceutical company ... treat inflammatory diseases, announced the hiring of Michael,V. ... Swanson has over 30 years of experience in ... in life sciences and specialty,pharmaceutical companies. Prior to ...
Cached Biology Technology:Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 2Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 3Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 4Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 5Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 6Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 2Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 3Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 4Amira Pharmaceuticals Hires Industry Veteran for CFO Position 2
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... University is proving its potential to impact global health. ... journal PLoS ONE , Rice alumnus Andrew Miller ... which costs $240, stacks up nicely against devices that ... of tuberculosis. Miller and colleagues at The Methodist ...
... not recognized as an animal until the 19th century, is ... have their genome sequenced. In a paper appearing in ... a team of researchers led by Daniel Rokhsar of the ... Genome Institute (JGI), report the draft genome sequence of the ...
... How well do you understand life in your own backyard? Cities ... aren,t visitors; they are an integral component, like trees in a ... the Earth,s people live in cities and the amount of paved ... Ohio, shouldn,t our sciences thrive in the city? Urban Ecosystem ...
Cached Biology News:Compact microscope a marvel 2Compact microscope a marvel 3Genome of ancient sponge reveals origins of first animals, cancer 2Genome of ancient sponge reveals origins of first animals, cancer 3Genome of ancient sponge reveals origins of first animals, cancer 4The real urban jungle 2
...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
Biology Products: